Early phase Health Technology Assessment COURSE

organised by the

Center for Health Technology Assessment, SEMMELWEIS UNIVERSITY, Budapest

COURSE DATE: 13 – 16 January 2026, 9:00 AM-4:00 PM

Health economic aspects of pharmaceutical R&D decisions



For Whom?

For representatives of health care innovators, investors and payers, HTA agencies, academic researchers and clinical research and market access specialists of the pharmaceutical industry or who are involved or interested in-, or influenced by decisions in pharmaceutical research and development.

Brief description

Early phase assessment of investigational medical technologies requires special skills in health technology assessment, economic modeling, and market research. Developers should explore realistic pricing assumptions and business models of these technologies before moving ahead or investing in a development program. The course - in addition to providing insights into theory - will mainly be based on case studies. Participants will construct economic models to judge the value-based price of investigational medical technologies, and evaluate their expected net present value to support indication selection and go, no-go decisions.

Participation will be face-to-face with limited seating.

Lecturers

Prof. Zoltán Kaló

Assoc. Prof. Balázs Nagy

Course fee	
Private sector	1200 €
Public & academic sector	800 €

HOW TO APPLY?

Send your filled application to: hta@semmelweis.hu by 20 December 2025

ADDITIONAL INFORMATION

Location: Beznák Aladár Room, Basic Medical Science Center, Semmelweis University, 1094 Budapest, Tűzoltó street 37-47.

Language: English only

Timing: Courses start at 9 AM, end at 4 PM

Skill requirements: Basic knowledge of statistics and/or pharmaceutical R&D, familiarity with MS Excel.

Equipment requirements: own laptop, MS Excel